A Food and Drug Administration (FDA)-regulated investigator-sponsored clinical study conducted at the Mayo Clinic investigating HAV in patients with chronic limb-threatening ischemia (CLTI)
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Human acellular vessel-Humacyte (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
Most Recent Events
- 18 Sep 2023 New trial record
- 11 Sep 2023 According to a Humacyte, Inc. Media Release, this trial was conducted at Mayo Clinic
- 11 Sep 2023 According to a Humacyte, Inc. Media Release, data from this study presented at the Midwestern Vascular Conference